You are about to leave DOPTELET.com/itp and go to an external page.
Please note that Sobi, Inc. is not responsible for the content of the website you are
about to visit.
Go back
You are about to leave DOPTELET.com/itp and go to an external page.
Please note that Sobi, Inc. is not responsible for the content of the website you are
about to visit.
Go back
Discover the Doptelet Copay
Assistance Program
Terms and Conditions
Sobi is providing this free tool to help you find healthcare providers in your area who may have experience treating chronic ITP. Neither Sobi nor MediFind pay healthcare providers to be listed in this tool and healthcare providers do not pay to be listed in the tool. Just because a healthcare provider is listed in the tool does not mean Sobi endorses their qualifications or recommends their medical care. The search results of healthcare providers are sorted by the distance from the location entered. Choosing a healthcare provider is an important decision requiring careful consideration. Sobi is not responsible for your choice or actions you take because of information provided by the tool.
Doptelet is an oral chronic ITP medication that helps increase platelet counts to 50,000 per microliter or more, in as few as 8 days, and can keep them lifted for an average of 12 total weeks.
Read all about ITP to learn how it affects the platelets in your blood and how it is diagnosed and treated.
WHAT IS ITP?Is chronic ITP affecting your day-to-day life? View information and guidance for managing low platelet counts.
SETTING GOALSSee if you’re eligible for any financial assistance programs.
FINANCIAL ASSISTANCE INFOSign up to receive tools and tips, including a free journal to help you track your platelet counts, symptoms, and treatment—plus you’ll get some surprises, too!
GET ITP TIPSIndication & Important Safety Information
What is DOPTELET (avatrombopag)?
Doptelet is a prescription medicine used to help treat low blood platelet counts in adults with chronic immune thrombocytopenia (ITP) when other treatments have not worked well enough. It is not known if Doptelet is safe or works in children.
Who should not receive Doptelet?
You should not receive Doptelet if you have ever had a blood clot. You should call your healthcare provider or get medical help right away if you have any of the signs or symptoms of a blood clot after taking Doptelet. They can be life-threatening or cause death.
Tell your healthcare provider if you are pregnant or breastfeeding, or plan to be while taking Doptelet. It is not known if Doptelet may have unintended side effects for your unborn baby or if Doptelet passes into breast milk. Do not breastfeed while taking Doptelet and for at least 2 weeks after the last dose.
Before taking Doptelet, you should tell your healthcare provider about all your medical conditions and medicines including vitamins, supplements, and herbal remedies.
What are the possible side effects of Doptelet?
For patients with chronic ITP, the most common side effects are headache, fatigue, bruising, nosebleeds, upper respiratory tract infection, joint pain, bleeding gums, purple or red spots on your skin (petechiae), and runny nose.
You Should Know: These are not all of the possible side effects of Doptelet. For more information, ask your healthcare provider or review the Prescribing Information at https://www.doptelet.com/doptelet.pdf.
If you suspect that you have experienced a side effect, call your healthcare provider. You may also report them to the US Food and Drug Administration (FDA) at 1-800-FDA-1088.
For further information, please see full Prescribing Information, including the Patient Information Leaflet.
What is DOPTELET® (avatrombopag)?
Doptelet is a prescription medicine used to help treat low blood platelet counts in adults with chronic immune thrombocytopenia (ITP) when other treatments have not worked well enough. It is not known if Doptelet is safe or works in children.
Who should not receive Doptelet?
You should not receive Doptelet if you have ever had a blood clot. You should call your healthcare provider or get medical help right away if you have any of the signs or symptoms of a blood clot after taking Doptelet. They can be life-threatening or cause death.
What is DOPTELET (avatrombopag)?
Doptelet is a prescription medicine used to help treat low blood platelet counts in adults with chronic immune thrombocytopenia (ITP) when other treatments have not worked well enough. It is not known if Doptelet is safe or works in children.
Who should not receive Doptelet?
You should not receive Doptelet if you have ever had a blood clot. You should call your healthcare provider or get medical help right away if you have any of the signs or symptoms of a blood clot after taking Doptelet. They can be life-threatening or cause death.
Tell your healthcare provider if you are pregnant or breastfeeding, or plan to be while taking Doptelet. It is not known if Doptelet may have unintended side effects for your unborn baby or if Doptelet passes into breast milk. Do not breastfeed while taking Doptelet and for at least 2 weeks after the last dose.
Before taking Doptelet, you should tell your healthcare provider about all your medical conditions and medicines including vitamins, supplements, and herbal remedies.
What are the possible side effects of Doptelet?
For patients with chronic ITP, the most common side effects are headache, fatigue, bruising, nosebleeds, upper respiratory tract infection, joint pain, bleeding gums, purple or red spots on your skin (petechiae), and runny nose.
You Should Know: These are not all of the possible side effects of Doptelet. For more information, ask your healthcare provider or review the Prescribing Information at https://www.doptelet.com/doptelet.pdf.
If you suspect that you have experienced a side effect, call your healthcare provider. You may also report them to the US Food and Drug Administration (FDA) at 1-800-FDA-1088.
For further information, please see full Prescribing Information, including the Patient Information Leaflet.
This website uses cookies. By continuing to
use this website, you consent to our use of these cookies. Read more about our use of cookies